Apollo Therapeutics has secured an exclusive license from Sunshine Lake Pharma for a clinical-stage dual receptor agonist targeting FGF21 and GLP-1.

KOSELUGO® (Selumetinib) Shows Significant Improvement in Response Rate Compared to Placebo in Adults with Symptomatic Neurofibromatosis Type 1.

Autolus Therapeutics has received FDA approval for AUCATZYL® (obecabtagene autoleucel-obe-cel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Marengo shares encouraging initial human safety, tolerability, and clinical activity results for its lead candidate, Invikafusp Alfa (STAR0602).

STORM Therapeutics reveals that it shared encouraging findings from its Phase 1 clinical trial of STC-15, an inhibitor targeting METTL3 RNA methyltransferase.

NGGT recently shared promising new data regarding NGGT002, their gene therapy candidate currently in clinical trials for addressing Phenylketonuria (PKU).

Theragent and CellVax Therapeutics have reported the initial dosing of a patient in their Phase 2 study of FK-PC101, a new personalized cancer immunotherapy.

Allogene Therapeutics shared promising Phase 1 results showcasing ALLO-316's potential in advanced renal cell carcinoma patients at SITC and IKCS.

Fate Therapeutics Shares Preclinical Data on FT836, a MICA/B-targeted CAR T-cell, at 2024 SITC Meeting.

Myeloid Therapeutics to Present on MT-303, a Pioneering mRNA CAR Targeting GPC3 in Advanced HCC, at SITC 2024.

OncoResponse Reports Phase 1 Findings of OR502, an anti-LILRB2 Antibody, in Patients with Advanced Cancer.

Harbour BioMed has filed an IND application for HBM9378/SKB378 to treat chronic obstructive pulmonary disease.